- Home
- ARHS vs SGP Comparison
ARHS vs SGP Comparison
Compare ARHS & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | SGP |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.8M | 932.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ARHS | SGP |
|---|---|---|
| Price | $6.89 | $24.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $10.78 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 1.2M | 99.4K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $1,379,222,000.00 | N/A |
| Revenue This Year | $7.23 | N/A |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | $14.30 | ★ N/A |
| Revenue Growth | ★ 8.51 | N/A |
| 52 Week Low | $6.17 | $20.15 |
| 52 Week High | $12.97 | $30.56 |
Technical Indicators
Market Signals| Indicator | ARHS | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 51.64 |
| Support Level | $6.17 | $20.72 |
| Resistance Level | $7.61 | $28.17 |
| Average True Range (ATR) | 0.27 | 2.18 |
| MACD | 0.13 | 0.08 |
| Stochastic Oscillator | 87.65 | 64.17 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.